Genix Pharmaceuticals（GENX）株式概要ジェニックス・ファーマシューティカルズ・コーポレーションは、カナダで栄養補助食品と医薬品を中心としたライフサイエンス関連製品の処方、製造、ライセンス、販売を行っている。 詳細GENX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 株式の流動性は非常に低い 収益が 100 万ドル未満 ( CA$0 )キャッシュランウェイが1年未満である +1 さらなるリスクすべてのリスクチェックを見るGENX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.015該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m928k2016201920222025202620282031Revenue CA$2.3Earnings CA$0.2AdvancedSet Fair ValueView all narrativesGenix Pharmaceuticals Corporation 競合他社Irwin NaturalsSymbol: CNSX:IWINMarket cap: CA$1.0mMercanto HoldingsSymbol: TSXV:MUSHMarket cap: CA$7.2mPsyched WellnessSymbol: CNSX:PSYCMarket cap: CA$4.1mCizzle BrandsSymbol: NEOE:CZZLMarket cap: CA$75.3m価格と性能株価の高値、安値、推移の概要Genix Pharmaceuticals過去の株価現在の株価CA$0.01552週高値CA$0.0452週安値CA$0.015ベータ0.471ヶ月の変化-25.00%3ヶ月変化n/a1年変化-57.14%3年間の変化-62.50%5年間の変化-92.31%IPOからの変化-94.00%最新ニュースBoard Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesBoard Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (in line with 3Q 2024). Net loss: CA$83.5k (loss widened 1.6% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 13Genix Pharmaceuticals Corporation announced that it expects to receive CAD 0.1 million in fundingGenix Pharmaceuticals Corporation announced that it has entered into a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.05 for the proceeds of CAD 100,000 on August 11, 2025. Each Unit will be comprised of one common share and one warrant. Each whole warrant will entitle the holder thereof to purchase one common share for a period of 2 years at a price of CAD 0.10. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. The transaction is subject to regulatory and stock exchange approval. Certain directors and officers of the company are expected to participate in the Offering.Reported Earnings • Jun 20First half 2025 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 1H 2024)First half 2025 results: CA$0.003 loss per share (further deteriorated from CA$0.002 loss in 1H 2024). Net loss: CA$159.2k (loss widened 9.8% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 01Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025.Reported Earnings • Feb 28Full year 2024 earnings released: CA$0.001 loss per share (vs CA$0.074 loss in FY 2023)Full year 2024 results: CA$0.001 loss per share (improved from CA$0.074 loss in FY 2023). Revenue: CA$4.1k (down 67% from FY 2023). Net loss: CA$73.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.Board Change • Feb 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.003 loss in 3Q 2023). Net loss: CA$82.2k (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 44% per year.Reported Earnings • Jun 28Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.004 loss in 2Q 2023). Net loss: CA$85.9k (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Feb 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$1.1m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$221k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$12k revenue, or US$9.1k). Market cap is less than US$10m (CA$2.37m market cap, or US$1.75m).お知らせ • Mar 20Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021. Location: Suite 1100-1111 Melville Street Vancouver British Columbia CanadaIs New 90 Day High Low • Jan 27New 90-day high: CA$0.25The company is up 35% from its price of CA$0.18 on 23 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period.分析記事 • Jan 17Did Genix Pharmaceuticals Corporation (CVE:GENX) Insiders Buy Up More Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...Is New 90 Day High Low • Jan 05New 90-day high: CA$0.22The company is up 29% from its price of CA$0.17 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 6.0% over the same period.お知らせ • Dec 17Genix Pharmaceuticals Corporation Announces Executive ChangesGenix Pharmaceuticals Corporation announced the appointment of Danny Lee as Chief Financial Officer. Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. Mr. Lee is a Chartered Professional Accountant with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee's experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions.Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$182.3k, with losses widening by 41% from the prior year.お知らせ • Sep 23Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of DirectorsGenix Pharmaceuticals Corporation announced that at its annual general meeting held on September 18, 2020, the shareholders elected Darryl Yea to the board of directors. Mr. Yea is currently president of Investco Capital Management Inc. He was formerly chairman, president and chief executive officer of Datawest Solutions Inc. Mr. Yea was a former member of the board of governors of the Vancouver Stock Exchange.お知らせ • Aug 07Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in fundingOn August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions of CAD 6,825 and issued 45,500 finders warrants pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing.株主還元GENXCA Personal ProductsCA 市場7D0%0.8%0.4%1Y-57.1%1.4%32.9%株主還元を見る業界別リターン: GENX過去 1 年間で1.4 % の収益を上げたCanadian Personal Products業界を下回りました。リターン対市場: GENXは、過去 1 年間で32.9 % のリターンを上げたCanadian市場を下回りました。価格変動Is GENX's price volatile compared to industry and market?GENX volatilityGENX Average Weekly Movementn/aPersonal Products Industry Average Movement7.5%Market Average Movement10.2%10% most volatile stocks in CA Market17.7%10% least volatile stocks in CA Market3.8%安定した株価: GENXの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のGENXのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1993n/aSina Piroozgenixpharm.comジェニックス・ファーマシューティカルズ・コーポレーションは、カナダで栄養補助食品と医薬品を中心にライフサイエンス関連製品の処方、製造、ライセンス供与、販売を行っている。同社は、抗ウイルス、抗インフルエンザ、感冒コロナウイルス経口およびスプレーハーブ製品であるFlu-X、腎臓の健康をサポートする栄養補助食品であるRenochlor、非インスリン依存性成人の血糖値を管理し、インスリン感受性を高めるハーブ健康補助食品であるSucanonを開発している。また、蜂プロポリスカプセル、カルシウムリキッドソフトジェル、シールオイルソフトジェル、マリンリピッドソフトジェル、レシチンソフトジェル、フィッシュオイルソフトジェル、EPOソフトジェル、スピルリナパウダーなどの栄養補助食品や医薬品、眼軟膏や目薬の販売も行っている。同社は以前Alta Natural Herbs & Supplements Ltd.として知られていたが、2019年6月にGenix Pharmaceuticals Corporationに社名変更した。同社は1993年に法人化され、カナダのバンクーバーに本社を置いている。もっと見るGenix Pharmaceuticals Corporation 基礎のまとめGenix Pharmaceuticals の収益と売上を時価総額と比較するとどうか。GENX 基礎統計学時価総額CA$918.36k収益（TTM）-CA$279.44k売上高(TTM)n/a0.0xP/Sレシオ-3.3xPER（株価収益率GENX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GENX 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$279.44k収益-CA$279.44k直近の収益報告Jan 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0046グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-73.3%GENX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/30 18:18終値2026/05/22 00:00収益2026/01/31年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genix Pharmaceuticals Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.
Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 01Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026.
Board Change • Mar 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (in line with 3Q 2024). Net loss: CA$83.5k (loss widened 1.6% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Sep 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 13Genix Pharmaceuticals Corporation announced that it expects to receive CAD 0.1 million in fundingGenix Pharmaceuticals Corporation announced that it has entered into a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.05 for the proceeds of CAD 100,000 on August 11, 2025. Each Unit will be comprised of one common share and one warrant. Each whole warrant will entitle the holder thereof to purchase one common share for a period of 2 years at a price of CAD 0.10. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. The transaction is subject to regulatory and stock exchange approval. Certain directors and officers of the company are expected to participate in the Offering.
Reported Earnings • Jun 20First half 2025 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 1H 2024)First half 2025 results: CA$0.003 loss per share (further deteriorated from CA$0.002 loss in 1H 2024). Net loss: CA$159.2k (loss widened 9.8% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 01Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025.
Reported Earnings • Feb 28Full year 2024 earnings released: CA$0.001 loss per share (vs CA$0.074 loss in FY 2023)Full year 2024 results: CA$0.001 loss per share (improved from CA$0.074 loss in FY 2023). Revenue: CA$4.1k (down 67% from FY 2023). Net loss: CA$73.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
Board Change • Feb 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 22Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.003 loss in 3Q 2023). Net loss: CA$82.2k (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 44% per year.
Reported Earnings • Jun 28Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.004 loss in 2Q 2023). Net loss: CA$85.9k (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Feb 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$1.1m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$221k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$12k revenue, or US$9.1k). Market cap is less than US$10m (CA$2.37m market cap, or US$1.75m).
お知らせ • Mar 20Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021. Location: Suite 1100-1111 Melville Street Vancouver British Columbia Canada
Is New 90 Day High Low • Jan 27New 90-day high: CA$0.25The company is up 35% from its price of CA$0.18 on 23 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period.
分析記事 • Jan 17Did Genix Pharmaceuticals Corporation (CVE:GENX) Insiders Buy Up More Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.22The company is up 29% from its price of CA$0.17 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 6.0% over the same period.
お知らせ • Dec 17Genix Pharmaceuticals Corporation Announces Executive ChangesGenix Pharmaceuticals Corporation announced the appointment of Danny Lee as Chief Financial Officer. Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. Mr. Lee is a Chartered Professional Accountant with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee's experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions.
Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$182.3k, with losses widening by 41% from the prior year.
お知らせ • Sep 23Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of DirectorsGenix Pharmaceuticals Corporation announced that at its annual general meeting held on September 18, 2020, the shareholders elected Darryl Yea to the board of directors. Mr. Yea is currently president of Investco Capital Management Inc. He was formerly chairman, president and chief executive officer of Datawest Solutions Inc. Mr. Yea was a former member of the board of governors of the Vancouver Stock Exchange.
お知らせ • Aug 07Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in fundingOn August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions of CAD 6,825 and issued 45,500 finders warrants pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing.
